The UK and US have hammered out a key commercial pact that will maintain no duties on British drug products being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to boost spending on medicines through the National Health Service (NHS). This pledge secures that import taxes on these vital exports will stay at nothing for a duration of three years.
This deal follows earlier statements to significantly raise import taxes on branded pharmaceutical imports, with figures mentioned as high as double the cost.
"This arrangement between the UK strengthens the worldwide climate for cutting-edge drugs and establishes long-overdue equity to transatlantic medicine commerce," an announcement noted.
Trade Impact
Drugs are one of the Britain's most significant export categories to the United States, which is easily the largest buyer for major companies like GSK and AstraZeneca.
Export figures indicate that in the year prior to last September, the UK exported pharmaceutical products totaling billions to the US. This value made up 17.4% of total UK exports in that timeframe.
"This guarantee protects work, stimulates investment and paves the way for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Detailed NHS Changes
The pact entails several specific changes from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to increase total health service expenditure on medicines from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be capped at 15%. In the past, rebates exceeded twenty percent.
Recent Tensions
The deal follows a long-running tension between the sector and the British authorities over spending levels and regulatory access.
This friction were intensified by claims that US patients were charged a premium for the same drugs than patients in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while major expansions have been pledged toward projects in the United States.
The Science Minister stated that the NHS must spend more on treatments, noting that its expenditure on drugs had declined as a share of its overall budget over the last ten years.
